Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis

EBioMedicine

Volumn 2, Issue 2, 2015, Pages 147-153

  Awatade, Nikhil T ^a   Uliyakina, Inna ^a   Farinha, Carlos M ^a   Clarke, Luka A ^a   Mendes, Karina ^a   Solé, Amparo ^b   Pastor, Juan ^b   Ramos, Maria Margarida ^a   Amaral, Margarida D ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Innovative treatments; Mutation specific therapies; Personalized medicine; Rare diseases

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; GENISTEIN; IVACAFTOR; LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN;

ARTICLE; BRONCHUS EPITHELIUM CELL; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; ELECTROPHYSIOLOGY; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ALVEOLUS CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSEPITHELIAL RESISTANCE; AMINO ACID SUBSTITUTION; CELL CULTURE; FEMALE; GENETICS; LUNG; MALE; METABOLISM; MISSENSE MUTATION; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC);

AMINO ACID SUBSTITUTION; AMINOPYRIDINES; BENZODIOXOLES; CELLS, CULTURED; CLINICAL TRIALS, PHASE III AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; LUNG; MALE; MUTATION, MISSENSE; PRECISION MEDICINE;

EID: 84943230777     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2014.12.005     Document Type: Article

References (24)

1. Amaral M.D. CFTR and chaperones: processing and degradation. J. Mol. Neurosci. 2004, 23(1-2):41-48.
2. Amaral M.D., Farinha C.M. Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr. Pharm. Des. 2013, 19(19):3497-3508.
3. Bell S.C., De Boeck K., Amaral M.D. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol. Ther. 2015, 145:19-34.
4. Bobadilla J.L., Macek M., Fine J.P., Farrell P.M. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum. Mutat. 2002, 19(6):575-606.
5. De Boeck K., Paskavitz J., Chen X., Higgins M. ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non-G551D-CFTR gating mutation: phase 3, part 1 results. Pediatr. Pulmonol. 2013, 48(36):292.
6. Eckford P.D., Ramjeesingh M., Molinski S., et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem. Biol. 2014, 21(5):666-678.
7. Farinha C.M., King-Underwood J., Sousa M., et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem. Biol. 2013, 20(7):943-955.
8. Farrell P.M. The prevalence of cystic fibrosis in the European Union. J. Cyst. Fibros. 2008, 7(5):450-453.
9. Fulcher M.L., Randell S.H. Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods Mol. Biol. 2013, 945:109-121.
10. He L., Kota P., Aleksandrov A.A., et al. Correctors of DeltaF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 2013, 27(2):536-545.
11. Holleran J.P., Glover M.L., Peters K.W., et al. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform. Mol. Med. 2012, 18:685-696.
12. Mendes F., Roxo-Rosa M., Dragomir A., et al. Unusually common cystic fibrosis mutation in Portugal encodes a misprocessed protein. Biochem. Biophys. Res. Commun. 2003, 311(3):665-671.
13. Moniz S., Sousa M., Moraes B.J., et al. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem. Biol. 2013, 8(2):432-442.
14. Moya-Quiles M.R., Mondejar-Lopez P., Pastor-Vivero M.D., et al. CFTR mutations in cystic fibrosis patients from Murcia region (southeastern Spain): implications for genetic testing. Clin. Genet. 2009, 76(6):577-579.
15. Press Release. Two 24-Week Phase 3 Studies of lumacaftor in Combination With ivacaftor Met Primary Endpoint With Statistically Significant Improvements in Lung Function (FEV1) in People With Cystic Fibrosis Who Have Two Copies of the F508del Mutation 2014, Vertex, (http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185).
16. Ramsey B.W., Davies J., McElvaney N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 2011, 365(18):1663-1672.
17. Rodrigues R., Magalhaes P.K., Fernandes M.I., et al. Neonatal screening for cystic fibrosis in Sao Paulo State, Brazil: a pilot study. Braz. J. Med. Biol. Res. 2009, 42(10):973-978.
18. Roxo-Rosa M., Xu Z., Schmidt A., et al. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(47):17891-17896.
19. Servidoni M.F., Sousa M., Vinagre A.M., et al. Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility. BMC Gastroenterol. 2013, 13(1):91.
20. Sosnay P.R., Siklosi K.R., Van G.F., et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet. 2013, 45(10):1160-1167.
21. The molecular genetic epidemiology of cystic fibrosis. Report of a Joint Meeting of WHO/ECFTN/ICF(M)A/ECFS 2004, 1-24. World Health Organization, (Downloadable at: http://www.cfww.org/WHO_index.asp).
22. Van Goor F., Hadida S., Grootenhuis P.D., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(46):18843-18848.
23. Van Goor F., Yu H., Burton B., Hoffman B.J. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros. 2014, 13(1):29-36.
24. Wang Y., Liu J., Loizidou A., et al. CFTR potentiators partially restore channel function to A561E, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR. Br. J. Pharmacol. 2014, 171(19):4490-4503.